Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1702 +/- Camrelizumab in Advanced Solid Tumors
NCT03871855Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Apr 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-1702 in solid tumor (advanced stage) (4 arms), sponsored by Hengrui. Primary endpoint: Number of Participants with Dose-Limiting Toxicities at 28 days. Started Apr 2019; status: terminated.
02
Drugs
SHR-1702
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03871855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871855.